Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · May 15, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The G-MAJOR clinical trial is focusing on how a special test called Gene Expression Classifier (GEC) can help improve the treatment of men with newly diagnosed prostate cancer that has a good chance of being treated successfully. The study aims to see how this test can be used in everyday medical care and how it might lead to better outcomes for patients. Researchers are currently looking for men between the ages of 18 and 74 who have been diagnosed with prostate cancer within the last nine months, have specific test results, and can provide tumor tissue from a biopsy for further testing.
If you decide to participate in this trial, you'll be helping researchers learn more about how GEC testing can affect treatment decisions. It's important to know that you cannot have had previous treatments for prostate cancer or have signs of more advanced disease to be eligible. If you qualify, you'll work closely with the study team, who will guide you through the process and keep you informed about what to expect. Your involvement could play a crucial role in improving care for future patients with prostate cancer.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.
- • Prostate biopsy tumor tissue (FFPR block) available for processing
- • Age 18 years or older
- • PSA \<20 ng/ml
- • Grade Group (GG) 1 cancer with \> 2 biopsy cores involved with cancer OR GG2 cancer
- • Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.
- Exclusion Criteria:
- • Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease
- • Nodal or metastatic prostate cancer (if staging imaging performed)
- • Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.
- • Prior prostate gene expression classier testing
About University Of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Chapel Hill, North Carolina, United States
Bronx, New York, United States
Ann Arbor, Michigan, United States
Philadelphia, Pennsylvania, United States
Grand Rapids, Michigan, United States
Detroit, Michigan, United States
Holland, Michigan, United States
Patients applied
Trial Officials
Todd Morgan, M.D.
Principal Investigator
University of Michigan
Daniel Spratt, M.D.
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials